paclitaxel + bevacizumab + carboplatin + topotecan

This combination regimen consists of **paclitaxel**, **bevacizumab**, **carboplatin**, and **topotecan**, all of which are individual anticancer pharmaceuticals. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division; carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis; topotecan inhibits topoisomerase I, leading to DNA damage; bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood supply. This combination leverages both cytotoxic chemotherapy and anti-angiogenic therapy. It is used primarily in advanced, recurrent, or resistant epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer. Regimens containing subsets of these drugs (e.g., paclitaxel + bevacizumab + topotecan, paclitaxel + bevacizumab + carboplatin) have been evaluated and approved for specific indications, but the exact four-drug combination is generally considered investigational or off-label and may be used in highly refractory cases, with data supporting significant clinical activity in these settings[1][7][9][12].